306 related articles for article (PubMed ID: 15766280)
41. A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
Li X; Hong L; Zhao Y; Jin H; Fan R; Du R; Xia L; Luo G; Fan D
Biochem Cell Biol; 2007 Dec; 85(6):741-50. PubMed ID: 18059532
[TBL] [Abstract][Full Text] [Related]
42. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
43. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
[TBL] [Abstract][Full Text] [Related]
44. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
45. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
46. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
47. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
48. P-glycoprotein effect on the properties of its natural lipid environment probed by Raman spectroscopy and Langmuir-Blodgett technique.
Oleinikov VA; Fleury F; Ianoul A; Zaitsev S; Nabiev I
FEBS Lett; 2006 Sep; 580(20):4953-8. PubMed ID: 16930597
[TBL] [Abstract][Full Text] [Related]
49. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter.
Marthinet E; Divita G; Bernaud J; Rigal D; Baggetto LG
Gene Ther; 2000 Jul; 7(14):1224-33. PubMed ID: 10918491
[TBL] [Abstract][Full Text] [Related]
50. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein.
Garrigues A; Nugier J; Orlowski S; Ezan E
Anal Biochem; 2002 Jun; 305(1):106-14. PubMed ID: 12018951
[TBL] [Abstract][Full Text] [Related]
51. A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles.
Bebawy M; Morris MB; Roufogalis BD
Anal Biochem; 1999 Mar; 268(2):270-7. PubMed ID: 10075817
[TBL] [Abstract][Full Text] [Related]
52. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids.
Wartenberg M; Hoffmann E; Schwindt H; Grünheck F; Petros J; Arnold JR; Hescheler J; Sauer H
FEBS Lett; 2005 Aug; 579(20):4541-4549. PubMed ID: 16083877
[TBL] [Abstract][Full Text] [Related]
53. Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells.
Gopinath VS; Thimmaiah P; Thimmaiah KN
Bioorg Med Chem; 2008 Jan; 16(1):474-87. PubMed ID: 17933543
[TBL] [Abstract][Full Text] [Related]
54. Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania.
Jiménez-Alonso S; Pérez-Lomas AL; Estévez-Braun A; Muñoz Martinez F; Chávez Orellana H; Ravelo AG; Gamarro F; Castanys S; López M
J Med Chem; 2008 Nov; 51(22):7132-43. PubMed ID: 18954040
[TBL] [Abstract][Full Text] [Related]
55. 20S-protopanaxadiol inhibits P-glycoprotein in multidrug resistant cancer cells.
Zhao Y; Bu L; Yan H; Jia W
Planta Med; 2009 Aug; 75(10):1124-8. PubMed ID: 19291609
[TBL] [Abstract][Full Text] [Related]
56. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
57. Bromocriptine modulates P-glycoprotein function.
Orlowski S; Valente D; Garrigos M; Ezan E
Biochem Biophys Res Commun; 1998 Mar; 244(2):481-8. PubMed ID: 9514944
[TBL] [Abstract][Full Text] [Related]
58. Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia.
Maraldi T; Bertacchini J; Benincasa M; Guida M; De Pol A; Liotta LA; Petricoin E; Cocco L; Marmiroli S
Int J Oncol; 2011 Feb; 38(2):427-35. PubMed ID: 21132263
[TBL] [Abstract][Full Text] [Related]
59. P-Glycoprotein is localized in intermediate-density membrane microdomains distinct from classical lipid rafts and caveolar domains.
Radeva G; Perabo J; Sharom FJ
FEBS J; 2005 Oct; 272(19):4924-37. PubMed ID: 16176266
[TBL] [Abstract][Full Text] [Related]
60. Does any relationship exist between P-glycoprotein-mediated multidrug resistance and intracellular calcium homeostasis.
Sulová Z; Seres M; Barancík M; Gibalová L; Uhrík B; Poleková L; Breier A
Gen Physiol Biophys; 2009; 28 Spec No Focus():F89-95. PubMed ID: 20093732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
